Meghan J. Mooradian

Oct 9, 2024 | nature.com | Ferdinandos Skoulidis |Ana Cobo |Meagan Montesion |Yi Yu |Natalie I. Vokes |Joseph Murray | +44 more

AbstractFor patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of anti-tumour activity and immune-related toxicities, when compared with treatment with PD-(L)1 inhibitors alone. However, there are currently no validated biomarkers to identify which patients will benefit from dual ICB1,2.

Aug 26, 2024 | nature.com | Meghan J. Mooradian |Florian J. Fintelmann |Thomas LaSalle |Alexander Graur |Sophia Z. Shalhout |Howard L. Kaufman | +4 more

AbstractImage-guided percutaneous cryoablation is an established minimally invasive oncologic treatment. We hypothesized that cryoablation may modify the immune microenvironment through direct modulation of the tumor, thereby generating an anti-tumor response in tumors refractory to immune checkpoint inhibition (ICI).

Aug 19, 2023 | mdpi.com | Meghan J. Mooradian |Ryan Sullivan

1. IntroductionCancer immunotherapy was transformed by the identification of key immune checkpoints and the subsequent clinical translation of immune checkpoint inhibitors (ICIs). The first of these, ipilimumab, blocks cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and was approved to treat advanced melanoma in 2011.

Jun 26, 2023 | physiciansweekly.com | Meghan J. Mooradian |Ryan Sullivan

The development of highly effective BRAF-targeted therapy and immune checkpoint inhibition for patients with advanced metastatic melanoma has transformed the treatment of this disease. More recently, these advances have moved into the resected, high-risk stage II and III settings.

May 15, 2023 | acsjournals.onlinelibrary.wiley.com | Meghan J. Mooradian |Ryan Sullivan

Abstract The development of highly effective BRAF-targeted therapy and immune checkpoint inhibition for patients with advanced metastatic melanoma has transformed the treatment of this disease. More recently, these advances have moved into the resected, high-risk stage II and III settings.